الفهرس 
ANATOMY OF THE ANTERIOR AND POSTERIOR EYEBALL SEGMENTSOnly 14 pages are availabe for public view
 |  | from | 214 |  |  |
| | | from | 214 | | |
Abstract
T
he treatment of many anterior and posterior segment disorders requires therapeutic levels of drugs in vitreous cavity.
The use of intraocular drugs for treatment of numerous intraocular disorders, this route of administration has the advantage of delivering drugs directly into the eye achieving a high therapeutic concentration with minimal systemic side effects. It is usually well tolerated but carries a small risk of intraocular complications.
Numerous pharmacologic agents have been off-label used for intracameral and intravitreal drug therapy:
• The use of intraocular drugs for treatment of bacterial, fungal, viral and protozoal intraocular infections.
• Corticosteroids are commonly used agents for control of posterior and severe anterior segment inflammatory diseases.
• Pharmacologic agents, currently including those with anti-VEGF activities, have shown promising results in control of intraocular neovascularization.
• Fibrinolytic agents such as tissue plasminogen activator which used in treatment of vitreous haemorrhage, premacular and subretinal haemorrhage.
• In case of proliferative vitreoretinopathy, the significant benefit of low-molecular-weight heparin for improving media clarity demonstrates its efficacy in inhibiting the cellular response in the vitreous cavity.
Certain off-label uses are appropriate and can even save you a lot of money. For example, some eye specialists use Genentech’s cancer drug beva-cizumab (Avastin), to inhibit the overgrowth of blood vessels in wet macular degeneration.